These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8796751)

  • 1. Clinical sequelae associated with squaric acid dibutylester topical sensitization.
    Foley S; Blattel SA; Martin AG
    Am J Contact Dermat; 1996 Jun; 7(2):104-8. PubMed ID: 8796751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts.
    Lee AN; Mallory SB
    J Am Acad Dermatol; 1999 Oct; 41(4):595-9. PubMed ID: 10495383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Questions raised by skin reactions observed during squaric acid dibutyl ester contact sensitization.
    Stinco G; Patrone P
    Contact Dermatitis; 2000 Jul; 43(1):52-3. PubMed ID: 10902598
    [No Abstract]   [Full Text] [Related]  

  • 4. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
    Shimaoka Y; Hatamochi A; Hamasaki Y; Suzuki H; Ikeda H; Yamazaki S
    J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An answer to some questions raised by skin reactions observed during squaric acid dibutylester contact sensitization.
    Happle R
    Contact Dermatitis; 2001 Sep; 45(3):189-90. PubMed ID: 11553162
    [No Abstract]   [Full Text] [Related]  

  • 6. Late reactions to the patch-test preparations para-phenylenediamine and epoxy resin: a prospective multicentre investigation of the German Contact Dermatitis Research Group.
    Hillen U; Jappe U; Frosch PJ; Becker D; Brasch J; Lilie M; Fuchs T; Kreft B; Pirker C; Geier J;
    Br J Dermatol; 2006 Apr; 154(4):665-70. PubMed ID: 16536809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunotherapy of multiple recurring warts. II. Reassessment of the use of squaric acid dibutylester (SADBE) (author's transl)].
    Claudy AL; Roche H
    Ann Dermatol Venereol; 1981; 108(10):765-7. PubMed ID: 7305218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pigmentation abnormalities in the course of topical immunotherapy of alopecia areata].
    Valsecchi R; Pansera B; Rossi A; Cainelli T
    G Ital Dermatol Venereol; 1989; 124(1-2):31-2. PubMed ID: 2527809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Textile dermatitis in patients with contact sensitization in Israel: a 4-year prospective study.
    Lazarov A
    J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):531-7. PubMed ID: 15324387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Squaric acid sensitization is not required for response in the treatment of alopecia areata.
    Vedak P; Kroshinsky D
    J Am Acad Dermatol; 2015 Sep; 73(3):471-6. PubMed ID: 26282797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of in vivo dose response and allergen-specific T cells in subjects contact-sensitized to squaric acid dibutyl ester.
    Camouse MM; Swick AR; Ryan CA; Hulette B; Gerberick F; Tinkle SS; Nedorost ST; Cooper KD; Stevens SR; Baron ED
    Dermatitis; 2008; 19(2):95-9. PubMed ID: 18413111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children.
    Mailhol C; Lauwers-Cances V; Rancé F; Paul C; Giordano-Labadie F
    Allergy; 2009 May; 64(5):801-6. PubMed ID: 19183418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contact immunotherapy with squaric acid dibutylester for warts [corrected].
    Iijima S; Otsuka F
    Dermatology; 1993; 187(2):115-8. PubMed ID: 8358098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
    Dall'oglio F; Nasca MR; Musumeci ML; La Torre G; Ricciardi G; Potenza C; Micali G
    J Dermatolog Treat; 2005 Feb; 16(1):10-4. PubMed ID: 15897160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
    Ajith C; Gupta S; Kanwar AJ
    J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical therapy of alopecia areata with squaric acid dibutylester.
    Case PC; Mitchell AJ; Swanson NA; Vanderveen EE; Ellis CN; Headington JT
    J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side-effects during treatment with SADBE.
    Frattasio A; Germino M; Cargnello S; Patrone P
    Contact Dermatitis; 1997 Feb; 36(2):118-9. PubMed ID: 9062760
    [No Abstract]   [Full Text] [Related]  

  • 18. Topical squaric acid dibutylester therapy for alopecia areata.
    Flowers FP; Slazinski L; Fenske NA; Pullara TJ
    Cutis; 1982 Dec; 30(6):733-6. PubMed ID: 6756800
    [No Abstract]   [Full Text] [Related]  

  • 19. Allergic contact dermatitis to proparacaine with subsequent cross-sensitization to tetracaine from ophthalmic preparations.
    Dannaker CJ; Maibach HI; Austin E
    Am J Contact Dermat; 2001 Sep; 12(3):177-9. PubMed ID: 11526525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angioedema After Squaric Acid Treatment in a 6-Year-Old Girl.
    Chen CA; Carlberg V; Kroshinsky D
    Pediatr Dermatol; 2017 Jan; 34(1):e44-e46. PubMed ID: 27699860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.